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Abstract: Gliomas are malignant brain tumors characterized by rapid spread and growth into
neighboring tissues and graded I–IV by the World Health Organization. Glioblastoma is the fastest
growing and most devastating IV glioma. The aim of this paper is to evaluate the biological effects of
two potent and selective Monoamine Oxidase B (MAO-B) inhibitors, Cmp3 and Cmp5, in C6 glioma
cells and in CTX/TNA2 astrocytes in terms of cell proliferation, apoptosis occurrence, inflammatory
events and cell migration. These compounds decrease C6 glioma cells viability sparing normal
astrocytes. Cell cycle analysis, the Mitochondrial Membrane Potential (MMP) and Reactive Oxygen
Species (ROS) production were detected, revealing that Cmp3 and Cmp5 induce a G1 or G2/M cell
cycle arrest, as well as a MMP depolarization and an overproduction of ROS; moreover, they inhibit the
expression level of inducible nitric oxide synthase 2, thus contributing to fatal drug-induced oxidative
stress. Cmp5 notably reduces glioma cell migration via down-regulating Matrix Metalloproteinases
2 and 9. This study demonstrated that our novel MAO-B inhibitors increase the oxidative stress
level resulting in a cell cycle arrest and markedly reduces glioma cells migration thus reinforcing the
hypothesis of a critical role-played by MAO-B in mediating oncogenesis in high-grade gliomas.
Keywords: Glioblastoma; MAO-B inhibitors; oxidative stress; migration
1. Introduction
Gliomas are the first brain tumors assumed to originate from the neuroglial stem or from progenitor
cells, characterized by inappropriate proliferation, infiltration into neighboring normal brain tissue and
the disruption of the normal functioning of the brain. Based on their histological appearance, gliomas
are conventionally classified as astrocytic, oligodendroglial or ependymal tumors and attributed by the
World Health Organization grades I–IV, which denote disparate levels of malignancy [1]. Glioblastoma
(GBM), a grade IV astrocytoma notoriously treatment–resistant brain cancer, is the greatest destructive
brain tumor, largely due to the limited effects of conventional post-surgical chemotherapeutic agents
and to irradiation [2].
A better understanding of the mechanism underlying the destructive nature of GBM could
improve radio-, chemo- and gene therapy. More effective GBM therapeutic strategies are urgently
needed. Unfortunately, the present therapies for high-grade gliomas are not an effective approach;
after preliminary diagnosis, patients receive a maximal surgical resection, concomitant radiotherapy
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and chemotherapy with Temozolomide (TMZ), the currently used chemoterapeutic agent for GBM
treatment. The TMZ raised the prognosis of GBM patients because it can cross the blood-brain barrier
and promote glioma cell death by alkylating DNA, even if TMZ resistance could be one of the major
reasons why treatments are not effective [3].
Monoamine Oxidase (MAO) catalyzes the oxidative deamination of a range of monoamines,
including 5-hydroxytryptamine (5-HT, serotonin), histamine and the catecholamines dopamine,
noradrenaline and adrenaline. The two isoenzymes of MAO (MAO-A and MAO-B) are present in
most mammalian tissues. They are not uniformly distributed in the human brain, and the principal
form in the basal ganglia is MAO-B. Over the past several decades, MAO-B inhibitors showed to have
potential use in the treatment of several neurodegenerative disorders, including Parkinson’s disease
and Alzheimer’s disease [4].
However, in the paper of Gabilondo et al. [5], it was reported that a remarkable and selective
increase in MAO-B activity is also detected in human gliomas. This could be explained by an augmented
number of astrocytes as well as a higher content of MAO-B in tumoral astrocytes with respect to
normal ones [5], highlighting that the overexpression of MAO-B could be related with high-grade
glioma, and thus defining MAO-B as a promising target for the development of novel therapies
for cancer. To better understand the role played by MAO-B inhibitors in the treatment of glioma,
the aim is to evaluate two newly synthesized compounds, namely Cmp3 and Cmp5 (Figure 1) [6],
along with two approved selective MAO-B inhibitors (deprenyl and safinamide). These compounds
were the best-in-class derivatives, within the hydrazothiazole scaffold, endowed with a potent and
selective hMAO-B inhibition in the low nanomolar range comparable to the clinically used drugs.
The Selectivity Index (SI) was expressed as IC50 hMAO-A/IC50 hMAO-B. They were shown to act as
reversible and competitive inhibitors. We also assessed the in vitro stability of pH and temperature in
forced conditions [7].
The aim of this work is to investigate the biological response of rat C6 glioma cell line and CTX
TNA2 astrocytes after treatment with these two novel MAO-B inhibitors in terms of cell proliferation,
apoptosis occurrence, inflammatory events and cell migration.
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(Cmp5), were selected and kept for further investigations (Figure 1). The effects of Cmp3 and Cmp5 
were evaluated by means of MTT assay on rat C6 glioma cell line compared with non-tumoral CTX 
TNA2 astrocytes. Cmp3 and Cmp5 were tested individually and compared to TMZ, the widely used 
drug in GBM treatment, to evaluate the effect on cell viability. 
Cmp3 and Cmp5 were administered at doses ranging from 3.125 up to 100 μM, whereas TMZ 
was administered at doses ranging from 15.625 up to 500 μM, based on the results already reported 
Figure 1. Structures and monoamine oxidase (MAO) inhibitory activity of the tested compounds.
2. Results
2.1. Effects of MAO-B Inhibitors on Rat C6 Glioma and on CTX TNA2 Astrocytes Cell Viability
Two novel, selective and potent MAO-B inhibitors, Compound 3 (Cmp3) and Compound 5
(Cmp5), were selected and kept for further investigations (Figure 1). The effects of Cmp3 and Cmp5
were evaluated by means of MTT assay on rat C6 glioma cell line compared with non-tumoral CTX
TNA2 astrocytes. Cmp3 and Cmp5 were tested individually and compared to TMZ, the widely used
drug in GBM treatment, to evaluate the effect on cell viability.
Cmp3 and Cmp5 were administered at doses ranging from 3.125 up to 100 µM, whereas TMZ
was administered at doses ranging from 15.625 u to 500 µ , based on the results already reported
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in literature [8,9]. In CTX TNA2 astrocytes, Cmp5 at 100 µM evidences cell viability percentages
of ~60% and ~50% after 24 h (Figure 2A) and 72 h of treatment (Figure 2B), respectively, whereas
Cmp3 at 100 µM does not affect the cell viability after 24 h (Figure 2A) and displays a cell viability
percentage of ~60% after 72 h (Figure 2B) of treatment. Conversely, TMZ at 500 µM is shown to present
cell viability percentages of ~70% and ~60% after 24 h (Figure 2C) and 72 h of treatment (Figure 2D),
respectively. Cmp3 and Cmp5 drastically reduce the viable C6 cells at doses between 50 and 100 µM
after 24 h and 72 h of treatment (Figure 3A,B, respectively), while TMZ at 500 µM shows similar C6
cell viability percentages reported for CTX TNA2 at the same time points. (Figure 3C,D, respectively).
These results lead us to keep 50 µM for the Cmp5 and 100 µM for the Cmp3 as suitable doses for
further investigations.
For the sake of comparison, we also tested for the first time two well-recognized, potent
and selective hMAO-B inhibitors (deprenyl and safinamide) in order to better corroborate our
proof-of-concept. Our newly synthesized compounds (Cmp3 and Cmp5) were nanomolar inhibitors
of hMAO-B working in the same range of these two approved drugs. Preliminary MTT experiments
regarding these two approved hMAO-B inhibitors against C6 and CTX TNA2 cells at 24 h and 72 h
(Figure S1) assessed that, at lower concentrations (0.625–10 µM), safinamide and deprenyl display
no statistically significant differences between tumoral and non-tumoral cell lines (a biological effect
which can be further stressed at higher concentrations), differently from what is shown by our novel
compounds (Cmp3 and Cmp5).
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Figure 2. MTT cell viability assay on CTX. (A,B) Histograms represent the viability dose-response of
CTX cells exposed to different concentrations of Cmp3 and Cmp5 (from 3.125 to 100 µM) for 24 h and
72 h, respectively. (C,D) Histograms represent the viability dose-response of CTX cells exposed to
different concentrations of TMZ (from 15.636 to 500 µM) for 24 h and 72 h. Proliferation was assessed
using MTT assay and normalized to control cells treated with DMSO (0.2% as final concentration).
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assessed at 92.94% and 92.28%, after 24 h and 48 h, respectively. As for cells exposed to Cmp3, the 
percentage of viable cells is comparable to that detected for DMSO both after 24 h (94.30%) and 48 h 
(92.47%). Apoptosis and/or necrosis are not observed. A slight, but not significant decrease in the 
viability of cells exposed to the Cmp5 can be established after 48 h of treatment (90.07%) as well as a 
rise in the percentage of the PI-stained necrotic population (8.05%) compared to that of DMSO-treated 
cells (6.47%). 
Figure 3. MTT cell viability assay on C6. (A,B) Histograms represent the viability dose-response of C6
cells exposed to different concentrations of Cmp3 and Cmp5 (from 3.125 to 100 µM) for 24 h and 72 h.
(C,D) Histograms represent the viability dose-response of C6 cells exposed to different concentrations
of TMZ (from 15.636 to 500 µM) for 24 h and 72 h. Proliferation was assessed using MTT assay and
normalized to control cells treated with DMSO (0.2% as final concentration).
2.2. Influence of Cmp3 and Cmp5 on Programmed Cell Death and Necrosis
The influence of MAO-B inhibitors on the induction of apoptosis in the C6 rat glioma cell cultures
after 24 h and 48 h of treatment is shown in Figure 4. DMSO-treated cells remain viable over the time of
the culture, being the percentage of cells stained negative for both Annexin-V and PI assessed at 92.94%
and 92.28%, after 24 h and 48 h, respectively. As for cells exposed to Cmp3, the percentage of viable
cells is comparable to that detected for DMSO both after 24 h (94.30%) and 48 h (92.47%). Apoptosis
and/or necrosis are not observed. A slight, but not significant decrease in the viability of cells exposed
to the Cmp5 can be established after 48 h of treatment (90.07%) as well as a rise in the percentage of the
PI-stained necrotic population (8.05%) compared to that of DMSO-treated cells (6.47%).
Molecules 2019, 24, 2005 5 of 16
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cells (G1 phase = 48.18%; S phase = 33.46%; G2/M phase = 18.37%). The Cmp3 causes a delay of the 
cell cycle in the G1 phase, being the percentage of cells increased in respect to DMSO-exposed cells 
(58.46%). Likewise, the percentage of cells found in the G1 phase after the Cmp5 administration is 
even higher, being assessed at 61.51%. In parallel, a consistent and remarkable change in the 
percentage of cells found in the S phase is registered in the presence of the Cmp3 (26.27%) and is 
further enhanced with the Cmp5 (18.34%). 
Figure 4. Induction of apoptosis and necrosis in C6 cells in the presence of Cmp5 and Cmp3. Percentages
of cells found in the various phases of cell death, analyzed by flow cytometry after staining with Annexin
V-FITC and propidium iodide (PI), are shown in the upper panel. Bars represent the percentage of viable
cells (u stained), cells in apoptosis (A nexin V-positive), cells in late apoptosis (Annexin V+PI), and
cells in necrosis (PI) as medians ± SD calculated from thre independent experiments. Representative
dual-par meter fluoresc nce density dot plot at 48 h are displayed in the lower panel.
2.3. Regulation of the Cell Cycle in the C6 Cells Exposed to Cmp3 and Cmp5
In order to establish whether the two MAO-B inhibitors could induce cell cycle arrest checkpoints
and decrease the C6 cells proliferation, the DNA content profiles of cultures exposed to the Cmp3
and Cmp5 after 24 h (Figure 5, upper panel) obtaining percentages of cells found in G1, S and G2
phase (Figure 5, lower panel) were analyzed. The DNA content fluorescence emission peaks and
bars related to the DMSO sample display a typical cell cycle profile, with proliferative and active
cells (G1 phase = 48.18%; S phase = 33.46%; G2/M phase = 18.37%). The Cmp3 causes a delay of the
cell cycle in the G1 phase, being the percentage of cells increased in respect to DMSO-exposed cells
(58.46%). Likewise, the percentage of cells found in the G1 phase after the Cmp5 administration is even
higher, being assessed at 61.51%. In parallel, a consistent and remarkable change in the percentage of
cells found in the S phase is registered in the prese ce of the Cm 3 (26.27%) and is further e hanced
with the Cmp5 (18.34%).
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Figure 5. Cell cycle analysis in C6 rat glioma cells in the presence of Cmp5 and Cmp3. The upper
panel displays the different DNA profile of cells after a 24 h treatment. Peaks are generated by the
emission of PI in the FL3 fluorescence channel. The percentage of cells in the G1, S and G2 phases
are shown in the bar graph in the lower panel. Bars represent medians ± SD from three independent
experiments. *** p < 0.002 between G1 phase of DMSO and Cmp5; *** p < 0.002 between S phase of
DMSO and Cmp5; ** p < 0.02 between G1 phase of DMSO and Cmp3.
2.4. Generation of Reactive Oxygen Species (ROS) and Depolarization of the Mitochondrial Membrane
Potential (MMP) in Cells Exposed to Cmp3 and Cmp5
Oxidative stress, as detected by the oxidation of CM-H2DCF-DA, significantly increases when the
C6 cells are exposed to Cmp3 an Cmp5 after 6 h (Figure 6). Both Cmp3 a d Cmp5 gen rate ROS,
registering a 2.4- (Cmp3) and a 4-fold ( ) increase in the DCF fluorescence intensity compared to
DMSO-treated culture. After a 24 h exposure, the Cmp3 dramatically rises the ROS production, with a
6.2-fold increase in respect to c lls expos d t DMSO while the DCF levels related to Cmp5-exposed
culture are comparable with th one exposed to DMSO. According to the induction of oxidative
stress, MMP is found depol ized in t e presenc of the two MAO inhibitors as shown in Figure 6.
In more detail, after 6 h treatment Cmp3 halves the MMP as c mpared to exposure to DMSO c ntrol.
The depolarization of the MMP caused by the Cmp3 exposure is remarkabl as compared t M P
depolarization u n Cmp5 treatm nt after the same exposure p riod, being the MMP l vel able
to the DMSO sample.
After longer xperimental times (24 h), Cmp3 retains a consistent and significant disturbance of
the MMP, in respect to the DMSO sample, being M an Fluorescence Inten ities (MFIs) assessed at
2.23 × 105 (Cmp3) and 3.13 × 105 (DMSO). In parallel, Cmp5 consid rably lowers MMP if compared to
6 h exposure, reveali g values comparable with those registered for Cmp3 (MFI of Cmp5 = 2.18 × 105)
(Figure 6).
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Figure 6. Gen ration of intracellula ti e oxygen species (ROS) and mit chondrial membrane
potential (MMP) modulation in C6 cel resence of Cmp5 and Cmp3. Bars in the lower panel
represent median values ± SD of the fl orescence intensity (MFI) gen rated by the oxidation of
CM-H2DCF-DA (generation of intracellular R S) and by the emission of TMRE (MMP) measured by
flow cytometry in cells exposed to MAO-B inhibitors. Representative fluorescence emission peaks are
shown in the upper panel and are provided to display the shift in the fluorescence emissions in the FL1
(FITC) and FL2 (PE) channels. **** p < 0.0005, *** p < 0.005, ** p < 0.02.
2.5. Nitric Oxide Synthase 1 (NOS-1), Nitric Oxide Synthase 2 (NOS-2) and Vascular Endothelial Growth
Factor (VEGF) Expression in Response to AO-B Inhibitors in Rat C6 cells
To identify the effects of Cmp3 at 100 µM and Cmp5 at 50 µM on the inflammatory event induction,
a Western Blot Analysis of neuronal NOS-1 and inducible NOS-2 was performed after 6 and 24 h of
treatment. After 6 h of treatment, no significant difference in NOS-1 expression level is recorded in
samples treated with both Cmp3 and Cmp5 with respect to the DMSO sample. After 24 h of treatment,
the NOS-1 expression level is significantly lower in cells treated with Cmp5 in respect to cells treated
with Cmp3. Moreov r, from 6 h to 24 h of treatment, a statistically significant decrease of the NOS-1
expression is detectable for Cmp3 and Cmp5 (Figure 7A,B).
After 6 h of treatment a statistically significant increase in the NOS-2 expression level is appreciable
in samples treated with both Cmp3 and Cmp5 with respect to DMSO sample. After 24 h of treatment
the NOS-2 expression is markedly reduced in cells treated with both Cmp3 and Cmp5 in respect to the
DMSO sample. A notable decrease of the protein expression in samples, exposed to both Cmp3 and
Cmp5, is reported from 6 h to 24 h of exposure (Figure 7A,C).
Furthermore, a western blot of VEGF, a major contributor of tumorigenesis and angiogenesis,
was performed. After 6 h, the protein is sig ificantly higher in cells tr ated with Cmp3 in r spect to
the DMSO sample; conversely, no significant differences are found in C6 cells treated with Cmp5 as
compared to DMSO. In addition, a significant reduction of the VEGF expression is evidenced for cells
treated with Cmp3 from 6 to 24 h (Figure 7A,D).
Molecules 2019, 24, 2005 8 of 16Molecules 019, 24, x FOR PEER REVIEW 8 of 17 
 
 
Figure 7. Western blotting analysis of NOS-1, NOS-2 and VEGF expression in rat C6 glioma cell lines 
treated with Cmp5 and Cmp3. (A) Cells treated with DMSO (0.2%) were loaded as the negative 
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of three separate experiments. The error bars on these graphs show standard deviation (± SD). 
Densitometric values analysed by ANOVA (post hoc application of Tukey’s multiple comparison test) 
return significant differences. **** p < 0.0001, *** p < 0.0002, ** p < 0.0005, * p < 0.005. 
2.6. Prostaglandin E2 (PGE-2) Secretion Level in Cells Exposed to Cmp3 and to Cmp5 
The ELISA assay for PGE-2 secretion was performed on the C6 cell line treated with Cmp5 and 
Cmp3 at 50 μM and 100 μM, respectively, for 24 and 72 h (Figure 8). As evidenced in Figure 8, both 
compounds notably enhanced the secretion of PGE-2 on rat C6 glioma cell lines at 24 h and 72 h 
compared to cells treated with DMSO. Furthermore, Cmp5 at 50 μM is responsible for a higher PGE-
2 secretion level with respect to cells treated with Cmp3 at 100 μM after 24 and 72 h. 
Figure 7. Western blotting analysis of NOS-1, NOS-2 and VEGF expression in rat C6 glioma cell lines
treated with Cmp5 and Cmp3. (A) Cells treated with DMSO (0.2%) were loaded as the negative control.
Each membrane has been probed with β–actin antibody to verify loading consistency. Western blot
is the most representative of three different experiments. (B–D) Histograms represent densitometric
measurements of proteins bands expressed as integrated optical intensity (IOI) mean of three separate
experiments. The error ba s o these graphs show s andard deviation (± SD). D nsi metric values
analys d by ANOVA (post hoc application of Tukey’s multiple comparison test) retu n significant
differences. **** p < 0.0001, *** p < 0.0002, ** p < 0.00 5, * p < 0.0 5.
2.6. Prostaglandin E2 (PGE-2) Secretion Level in Cell sed to Cmp3 and to Cmp5
The ELISA assay for PGE-2 secretion was perf r ed on the C6 cell line treated with Cmp5 and
Cmp3 at 50 µM and 100 µM, respectively, for 24 and 72 h (Figure 8). As evidenced in Figure 8, both
compounds notably enhanced the secretion of PGE-2 on rat C6 glioma cell lines at 24 h and 72 h
compared to cells treated with DMSO. Furthermore, Cmp5 at 50 µM is responsible for a higher PGE-2
secretion level with respect to cells treated with Cmp3 at 100 µM after 24 and 72 h.
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Figure 8. ELISA assay in C6 rat glioma cells in the presence of Cmp3 and Cmp5. PGE2 secretion levels,
measured after 24 and 72 h, are reported as pg/mL/OD MTT values. Data shown are the mean (± SD)
of three different experiments. Cmp5 50 µM vs. ctrl, *Cmp3 100 µM vs. Cmp5 50 µM p < 0.05.
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2.7. Effects of MAO-B Inhibitors on Cell Migration and Metalloproteinases Expression
A transwell migration assay was executed using an 8 µm pore size polycarbonate membrane
in C6 cells in the absence or presence of 100 µM Cmp3 and 50 µM Cmp5. Cells were exposed for
24 h to medium with or without chemoattractant (Foetal Bovine Serum) in the presence or absence of
compounds where migrated cells were then stained with crystal violet. Both compounds provoke a
remarkable reduction of cell migration with respect to the DMSO sample (Figure 9). To evaluate the
degradation of extracellular matrix, Matrix Metalloproteinases 2 and 9 (MMP-2 and MMP-9) expression
levels were investigated with Western Blot Analysis. The MMP-2 expression is significantly reduced
when cells are treated with Cmp5 with respect to the DMSO sample after both time points. After 24 h
of treatment, the MMP-2 expression appears significantly increased in cells treated with Cmp3 in
respect to DMSO and Cmp5 samples (Figure 10A,B). In parallel, the MMP-9 protein level is markedly
augmented in cells treated for 6 h with Cmp3 compared to Cmp5 and DMSO samples. After 24 h
of treatment, the MMP-9 expression was markedly reduced in cells treated with both compounds
in respect to the DMSO sample (Figure 10 A,C). In addition, Cmp3 provokes a marked reduction of
MMP-9 from 6 to 24 h treatment, whereas Cmp5 downregulates both MMPs (Figure 10A–C).
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Figure 9. Transwell migration assay in C6 rat glioma cell line in the presence of Cmp5 and Cmp3. Dose
treatments are 50 and 100 µM for Cmp5 and Cmp3, respectively (upper panel). Histogram represents
densitometric analysis determined by quantifying thresholded area for violet color in ten fields for
each of three slides per sample (lower panel). Data are presented as mean ± standard deviation. Cmp5
50 µM versus ctrl; *Cmp3 100 µM versus ctrl: p < 0.0001.
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for TMZ, which is the most used drug in GBM. Surprisingly, we also found that Cmp3 and Cmp5 
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Figure 10. Western blotting analysis of MMP-2, MMP-9 expression in rat C6 glioma cell lines treated
with Cmp5 and Cmp3. (A) Cells treated with D SO (0.2%) were loaded as negative control. Each
membrane has been probed with β–actin antibody to verify loading consistency. Western blot is
the ost representative of three different experiments. (B,C) Histograms represent densitometric
measurements of proteins bands expressed as integrated optical intensity (IOI) mean of three separate
experiments. The error bars on these graphs show standard deviation (± SD). **** p < 0.0001,
*** p < 0.0002, ** p < 0.0005, * p < 0.005.
3. Discussion
It is widely reported in scientific literature that the MAO-B activity appears to increase with
aging as well as in patients affected by neurodegenerative conditions including Parkinson’s disease
and Alzheimer’s disease, thus explaining the administration of MAO-B i hibitors t treat the
abovementioned diseases [10]. Nevertheless, Gabilondo and colleagues demonstrated a significant and
selective i crease in the MAO-B acti ity in human gliomas compared with non-tumoral tissues [5,11].
Therefore, we evaluated for the first time the biological effects of two novel MAO-B inhibitors,
which were synthesized in our medicinal chemistry laboratory, on the C6 glioma cell line and on CTX
TNA2 non-tumoral astrocytes, in terms of cell proliferation, apoptosis occurrence, inflammatory events
and cell migration in or er t improve the design and the ssessment of anti-glioma therapies.
The two novel MAO-B inhibitors, Cmp3 and Cmp5, appeared as promising mol cules targeting
MAO-B r porting in glioma cells a percentag of cell viability notably lower than that recorded for
TMZ, which is the most used drug in GBM. Surprisingly, we also found that Cmp3 and Cmp5 were
capable of blocking tumor cell proliferation while sparing normal astr cytes. We further investigated
this aspect by flow cyto etric Annexin-V assay discovering that the bl ck of tumor cell proliferation
was unrelated t apoptosis or to necrosis.
As commonly reported in scientific literature in different experimental models of glioma, several
cyt toxic drugs provoked an nti-proliferative effect inducing the G1 or G2/M cell cycle phase
accumulation leading to a final cell cycle arrest [12,13]. Based on this knowledge, the cell cycle phases
Molecules 2019, 24, 2005 11 of 16
were measured by flow cytometry to further elucidate the biological mechanism underlying MAO-B
inhibitory activity in tumor cells. We found that our novel MAO-B inhibitors, especially Cmp5, were
responsible for an accumulation of C6 cells in the G1 phase and in parallel to a notable reduction of
cells in the S phase. Our data are in accordance to previous studies demonstrating that MAO inhibitors,
both MAO-A and MAO-B inhibitors, as well as pargyline and tranylcypromine, are able to inhibit the
proliferation of prostate and breast cancer cells [14,15].
Furthermore, we measured the ROS production leading us to assume that the ROS increase after
treatment with both MAO-B inhibitors could be largely responsible for the reduction of the S phase of
C6 glioma cells, as already hypothesized [16]. It is possible to assume that our data on cell cycle report
a clear temporal distinction between the ROS induction by Cmp3 and Cmp5. Indeed, Cmp5 is an
early ROS inducer, whereas Cmp3 is a stronger, but late inducer. This could represent a valuable and
promising result considering that the increase of intracellular ROS can be therapeutically exploited. In
fact, several chemotherapeutic agents may exert a selective toxic activity against cancer cells because
they raise oxidative stress forcing the already stressed cells behind their limit [17]. Given that a notable
reduction of the MMP predicts a marked oxidative stress, our data are further supported by the
MMP, which appears markedly depolarized when the two MAO inhibitors are administrated. This
trend could be related to the chemical-physical differences between the two compounds. Cmp3 has a
CLogP value of 4.30, whereas Cmp5 has a CLogP value of 4.09, thus reinforcing our data on the early
mitochondrial membrane depolarization possibly due to the Cmp3 higher lipophilicity (associated to
a better membrane permeability). The ability of our tested compounds to increase the base level of
oxidative stress is also confirmed by the augmented PGE-2 secretion level measured after 24 h and 72 h
of treatment, thus underlining the critical role played by oxidative stress in the mechanism of action of
chemotherapeutic agents, as also hypothesized by Sun and colleagues [18].
Since it is well known that NOS activation is regulated by ROS and Reactive Nitrogen Species and
that NOS-2 is implicated in human malignant tumors [19,20], we investigated the NOS expression.
At an early stage, both our compounds did not modify the expression level of constitutive subtype of
NOS-1, whereas they evidenced a remarkable ability to upregulate the expression level of inducible
isoform NOS-2, thus contributing to the dramatic induction of a fatal drug-induced oxidative stress.
However, the tested compounds did not reveal an up-regulation of NOS-2 at long time exposure, this
could be due to a possible cell mechanism of resistance triggered after a longer drug administration.
Malignant gliomas are also well known for high vascularization suggesting that the recruitment
of VEGF, the most important contributor of angiogenesis, represents a critical step for the progression
of this malignancy [21]. Given that the VEGF expression is Nitric Oxide dependent [22], we evaluated
the protein level, finding as expected, that the signaling pathway triggered by MAO-B inhibitors,
involving ROS and NOS-2, is also supported by VEGF recruitment. It appears significantly augmented
only at an early stage with Cmp3, thus supporting the hypothesis of the oxidative stress-promoted
mechanism of action.
Moreover, the acquisition of a migratory phenotype is the prerequisite for its metastatic spreading
and invasive potential [23]. Based on this evidence, we evaluated the effects of Cmp3 and Cmp5
on C6 cell migration. Surprisingly, both novel MAO-B inhibitors markedly reduced glioma cell
migration, thus significantly preventing the invasiveness of brain tumors and their ability to infiltrate
the neighbouring tissues as already demonstrated for several anti-glioma agents [24,25]. To clarify
the molecular mechanism underlying this result, we evaluated the expression levels of MMP-2 and
MMP-9, two proteases of the Matrix Metalloproteinase family involved in the remodeling and turnover
of local extracellular matrix components. The MMP-2 and MMP-9 received particular attention given
that their increased expression appeared related to the malignant potential of several types of cancer,
including human gliomas [26]. We evidenced that Cmp5 notably reduces glioma cell migration via the
down-regulation of MMP-2 and MMP-9. These results are in agreement with data reported in scientific
literature such as those reported by Webb [27] who explained that an up-regulation of MMP-2 and
MMP-9 may result in cellular invasion, migration and in cancer metastasis. On the other hand, Cmp3,
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downregulating MMP-9 only at long time exposure, led us to assume that an alternative pathway
could be involved in the reduction of cell migration.
In conclusion, this study demonstrates that our novel MAO-B inhibitors are able to contrast glioma
proliferation by arresting the cell cycle and drastically increasing oxidative stress conditions, as well as
the invasiveness by markedly reducing the migration of malignant cells. These findings reinforce the
critical role played by MAO-B in mediating oncogenesis in high-grade glioma. Therefore, targeting the
MAO-B protein could be a new approach to achieve improved therapeutic efficacy for glioblastoma.
4. Materials and Methods
4.1. Drugs and Reference Inhibitors
The two compounds were synthesized, purified and characterized as recently reported [6], whereas
the two approved hMAO-B inhibitors (deprenyl and safinamide) were provided by Sigma-Aldrich
(Milan, Italy). CLogP values for the newly-synthesized compounds were generated by ChemBioDraw
Ultra 12.0.
4.2. Cell Lines
C6 rat glioma cell line (ECACC 92090409, Sigma Aldrich, Milan, Italy) and CTX/TNA2 rat
astrocytes (ATCC CRL-2006TM) were cultured in Ham’s F12 and in DMEM high Glucose medium,
respectively, supplemented with 10% of foetal bovine serum (FBS), 1% of penicillin/streptomycin and
1% of l-glutamine (all purchased by EuroClone, Milan, Italy). Cell cultures were maintained in an
incubator in a humidified atmosphere with 5% CO2 at 37 ◦C.
4.3. MTT Assay
The C6 and CTX/TNA2 cells were seeded at cell density of 8000/well into a 96-well tissue
culture plate. The metabolic activity of C6 and CTX/TNA2 cell lines was evaluated after 24 h
and 72 h of treatment with Cmp3 and Cmp5 at 3.125, 6.25, 12.5, 25, 50, 100 µM and with
TMZ at doses ranging from 15.625 up to 500 µM, on a 96-well polystyrene plate through MTT
(3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (Sigma Aldrich, Milan, Italy).
The assay is based on the capability of viable cells to reduce MTT into a colored formazan product.
Compounds were dissolved in DMSO with a final concentration of 0.2%. At the established time
points, the medium was replaced by a new one containing 0.5 mg/mL MTT and probed with cells for
4 h at 37 ◦C. The plate was incubated in DMSO solution for 30 min at 37 ◦C to solubilize salts and then
read at 540 nm by means of a microplate reader (Multiskan GO, Thermo Scientific, MA, USA). Values
obtained in the absence of cells were considered as background. Viability was normalized to control
cells treated with the vehicle DMSO.
4.4. Detection of Apoptosis by Flow Cytometry
C6 rat glioma cells (2.375 × 105/well) were cultured in 6-well plates for 24 h at 37 ◦C in a humidified
atmosphere. The growth medium was then removed and the cells were subsequently exposed to
treatments. Apoptosis detection was performed after 24 and 48 h collecting supernatants in tubes,
cells were washed once with PBS at room temperature. Next, cells were trypsinized and collected by
centrifugation together with supernatants. Apoptotic and necrotic cells were detected after staining
cells with an Annexin-V and Propidium Iodide (PI) kit (eBioscience, Thermo Fisher Scientific, MA, USA),
following the manufacturer’s instructions. Briefly, samples were incubated in 197 µL of binding buffer
and 3 µL of Annexin-V FITC for 15 min at room temperature in the dark. Volumes were afterwards
doubled, cells were washed once by centrifugation and re-suspended into 300 µL of binding buffer
with PI. The fluorescence was determined by a CytoFlex flow cytometer (Beckman Coulter, CA, USA).
FITC fluorescence (FL-1) was analyzed by a 530/30 band pass filter, and PI fluorescence (FL-3) by a
650 nm long pass filter. Data acquisition (2 × 104 events/sample) and data analysis were performed
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with the CytExpert Software (Beckman Coulter, CA, USA). The percentages of viable cells (Annexin
V−; PI−) were detected in the lower left quadrant (unstained) of density plots, as well as the cells
in apoptosis (Annexin V+/PI−, lower right quadrant), late apoptosis (Annexin V+/PI+, upper right
quadrant) and necrosis (Annexin V−/PI+, upper left quadrant).
4.5. Cell Cycle Analysis
The C6 rat glioma cells were seeded and exposed as previously described in this section. After
24 h exposure, the medium was removed and cells were washed once with PBS, trypsinized and
collected by centrifugation. Next, the cells were counted by means of Trypan blue dye exclusion test
and 3 × 105 cells/sample were fixed in cold ethanol 70% v/v and kept at 4 ◦C overnight. After that, the
cells were gently washed with cold PBS and centrifuged at 2700 g for 10 min at 4 ◦C. After having
discarded supernatants, each sample was incubated in 300 µL of the staining solution containing
PBS without calcium and magnesium, RNase 100 µg/mL (stock solution 10 mg/mL in 10 mM sodium
acetate buffer, pH 7.4) and PI 10 µg/mL (stock solution 1 mg/mL in water) (all purchased by Sigma
Aldrich, MI, USA) and kept at 4 ◦C overnight in the dark. PI fluorescence was detected by a flow
cytometer equipped with a 488 nm laser (CytoFlex flow cytometer, Beckman Coulter, CA, USA) in the
FL-3 channel (620 nm of wavelength emission). 2 × 104 events/sample were collected and analyzed
with CytExpert Software (Beckman Coulter, CA, USA). The percentage of cells in G1, S, or G2 phase of
the cell cycle were calculated after mathematical modeling of histograms using the FCS Express Flow
Cytometry Data Analysis (De Novo Software, CA, USA).
4.6. Flow Cytometry Analysis of ROS and MMP
The C6 rat glioma cells were cultured and stimulated as described for the apoptosis
assay. The intracellular generation of ROS was determined using the chloromethyl derivative
of 2′,7′-Dichlorofluorescein Diacetate (DCF-DA) (CM-H2DCF-DA, Molecular Probes, Invitrogen,
CA, USA), an oxidation-sensitive probe, while the fluctuations of the mitochondrial membrane
potential was monitored by means of the TMRE (Tetramethylrhodamine, Ethyl Ester) Assay Kit
(Abcam, Cambridge, UK). After 6 and 24 h, exposure medium was removed and cells were incubated
with PBS/FBS 10% and CM-H2DCFDA 2.5 µM at 37 ◦C in a humidified atmosphere in the dark. After
30 min, 100 nM TMRE was added and cells were incubated for an additional 30 min. Next, cells were
washed once with PBS, trypsinized and collected by centrifugation. After having resuspended cells in
30 µL of PBS, DCF and TMRE fluorescence emissions were measured by flow cytometry (CytoFlex
flow cytometer, Beckman Coulter, CA, USA) at an excitation wavelength of 488 nm and an emission
wavelength of 527 nm (DCF-FITC) and 575 nm (TMRE-PE). Mean Fluorescence Intensity (MFI) was
obtained by histogram statistics using the CytExpert Software (Beckman Coulter, CA, USA). Individual
values of MFI were normalized on negative controls (unstained samples) and are provided as mean
values of MFI ratio ± SD.
4.7. Western Blot Analyses
The C6 cell lysates (20 µg) were electrophoresed and transferred to the nitrocellulose membrane.
Nitrocellulose membranes, blocked in 5% of non-fat milk in PBS 0.1% Tween-20, were probed with
mouse monoclonal anti-β actin antibody (antibody dilution 1:5000) (A5316 Sigma, MO, USA), rabbit
polyclonal anti-VEGF anti-NOS-2 antibodies (antibodies dilution 1:200) (sc-152, sc-651, respectively,
both purchased by Santa Cruz biotechnology, CA, USA), mouse monoclonal anti-HIF-1α, anti-MMP-9,
anti-MMP-2, anti-NOS-1 antibodies (antibodies dilution 1:200) (sc-5354, sc-393859, sc-13595, sc-5302,
respectively, all purchased by Santa Cruz biotechnology, CA, USA), then incubated in the presence of
specific enzyme conjugated IgG horseradish peroxidase. Immunoreactive bands were detected by ECL
system (Amersham Int., Buckunghamshire, UK) and analyzed by densitometry. Densitometric values,
expressed as Integrated Optical Intensity (IOI), were estimated in a CHEMIDOC XRS system by the
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QuantiOne 1-D analysis software (BIORAD, Richmond, CA, USA). Values obtained were normalized
based on densitometric values of loading control β-actin.
4.8. ELISA Test for PGE-2
The PGE-2 secretion in the culture medium was detected by following the instructions provided
by the manufacturer’s protocol. EIA kit (Enzo Life Sciences, Farmingdale, NY, USA) was used to
measure PGE-2 concentrations. The absorption values were obtained by the spectrophotometric
reading of plates at 450 and 405 nm, respectively, by means of a microplate reader (Multiskan GO,
Thermo Scientific, MA, USA). Secretion levels of PGE-2 were analyzed in different wells after treatment
with Cmp5 at 50 µM and Cmp3 at 100 µM, normalized for relative optical density (pg/mL/OD) as
previously determined by the MTT assay.
4.9. Transwell Migration Assay
The C6 cell migration was evaluated by means of a 24-well Transwell Boyden chamber containing
8 µm pore size membranes (Corning, Lowell, MA, USA). For this purpose, suspended C6 rat glioma
cells were separately treated with 50 µM Cmp5 and 100 µM Cmp3 in serum-free Ham’s F12 at cell
density of 50,000/150 µL, and then added to the upper chamber of a 8 µm pore size insert. Ham’s F12
supplemented with 10% FBS was added to the lower chamber as a chemoattractant and allowed to
migrate towards a 10% FBS containing medium present in the lower chamber. Cells were incubated
for 24 h at 37 ◦C, the non-migrating cells on the upper chamber were then removed with the aid of
a cotton swab, whereas the cells migrated to the lower surface of the membrane were stained with
crystal violet for 10 min at room temperature. Images were captured at 20x magnification with a light
microscope (Leica DM 4000, Leica Cambridge Ltd., Cambridge, UK) equipped with a Leica DFC 320
camera (Leica Cambridge Ltd.). Images were analyzed by means of Leica Application Suite–X (LAS-X)
analysis software. The migration rate was calculated as the area covered by stained cells, given that
they represent the migrated cells.
4.10. Statistics
Statistical analysis was executed with GraphPad 7 software using t-test and Ordinary One-Way
ANOVA followed by post-hoc Tukey’s multiple comparisons tests. Values of p < 0.05 were considered
statistically significant.
Supplementary Materials: The following are available online. Figure S1: MTT cell viability assay on C6 and CTX
TNA2. (A, C) Histograms represent the viability dose-response of C6 cells exposed to different concentrations
of deprenyl and safinamide (0.625 up to 10 µM) for 24 h and 72 h. (B, D) Histograms represent the viability
dose-response of CTX cells exposed to different concentrations (0.625 up to 10 µM) of deprenyl and safinamide for
24 h and 72 h. Proliferation was assessed using MTT assay and normalized to control cells treated with DMSO
(0.2% as final concentration).
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